ScreenerHero
GHGuardant Health, Inc.
NAS · US · Healthcare · Diagnostics & Research · guardanthealth.com
167.34USD+2.45%Mkt Cap: 21.92B $P/E: —

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutati…

Industry Peers

Diagnostics & Research
Screen all
TMO
Thermo Fisher Scientific Inc.
$226.85BUSDP/E 33.1
DAP
Danaher Corporation
$142.58BUSDP/E 38.5
DHR
Danaher Corporation
$151.78BUSDP/E 38.6
LONN
Lonza Group AG
$47.21BUSDP/E 38.3
NTRA
Natera, Inc.
$46.86BUSD
IDXX
IDEXX Laboratories, Inc.
$44.35BUSDP/E 39.5
A
Agilent Technologies, Inc.
$44.14BUSDP/E 31.4
IQV
IQVIA Holdings Inc
$41.03BUSDP/E 31.0
WAT
Waters Corporation
$40.83BUSDP/E 105.8
ILU
Illumina, Inc.
$30.40BUSDP/E 40.4
ILMN
Illumina, Inc.
$30.95BUSDP/E 38.2
MTD
Mettler-Toledo International, Inc.
$28.55BUSDP/E 32.1
LH
Labcorp Holdings Inc.
$26.80BUSDP/E 27.4
DGX
Quest Diagnostics Incorporated
$26.68BUSDP/E 25.6
MEDP
Medpace Holdings, Inc.
$16.98BUSDP/E 35.8
ERF
Eurofins Scientific SE
$13.65BUSDP/E 25.3
CRL
Charles River Laboratories International, Inc.
$13.84BUSD
RVTY
Revvity Inc. Common Stock
$13.33BUSDP/E 57.4
BIM
bioMérieux S.A.
$9.55BUSDP/E 19.1
QIA
Qiagen N.V.
$8.69BUSDP/E 22.8

Key Statistics

Company
Market Cap21.92B $
Enterprise Value23.17B $
Revenue (TTM)1.18B $
Gross Profit633.01M $
Net Income (TTM)-416.28M $
Revenue/Share9.142 USD
Last Price167.34 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees2.5K
CountryUS
SectorHealthcare
IndustryDiagnostics & Research
ISINUS40131M1099
Valuation
P/E (Trailing)—
P/E (Forward)-372.96
PEG—
EV/EBITDA-53.82
EV/Revenue19.59
P/S19.04
P/B-100.65
EPS (TTM)-3.61
EPS (Forward)-0.45
52W Range
53.4092% of range176.58
52W High176.58 USD
52W Low53.40 USD
Profitability
Gross Margin64.46%
Oper. Margin-38.25%
EBITDA Margin-36.39%
Profit Margin-42.39%
ROE419.18%
ROA-20.67%
Growth
Revenue Growth44.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-184.76M $
CapEx (TTM)48.31M $
FCF Margin2.25%
FCF Yield0.12%
Net Debt643.54M $
Net Debt/EBITDA-1.49
Balance Sheet
Debt/Equity-17.22
Current Ratio4.03
Quick Ratio3.53
Book Value/Sh-1.6680 USD
Cash/Share7.850 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)194.29 USD
Upside (mean)+16.1%
Target Range105.00 USD – 225.00 USD
$105.00+16.1% to mean$225.00
# Analysts24
Ownership
Shares Out.134.20M
Float129.39M
Insiders3.97%
Institutions100.91%
Short Interest
Short Ratio4.5d
Short % Float8.87%
Short % Out.8.51%
Shares Short11.42M
Short (prev mo.)12.14M
Technical
SMA 50152.36 (+9.8%)
SMA 200113.66 (+47.2%)
Beta1.59
S&P 52W Chg18.16%
Avg Vol (30d)2.10M
Avg Vol (10d)2.26M
Technical Indicators
RSI (14)57.0
MACD3.7597
MACD Signal4.1480
MACD Hist.-0.3883
BB Upper172.97 USD
BB Middle157.14 USD
BB Lower141.32 USD
BB Width20.14%
ATR (14)7.746 USD
Vol Ratio (20d)1.18x